Evidence map›Paper›PMID 42689189›Full record

ArticleCureus2026

A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report.

Pujita Julakanti, Victor Hugo Spitz, Gerard Runko, Laura Ziton

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pujita JulakantiInternal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Victor Hugo SpitzInternal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Gerard RunkoInternal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Laura ZitonFamily Medicine, Northwest Medical Center, Margate, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Partner and Localizer of BRCA2 (PALB2) gene is a tumor suppressor gene with a role in DNA repair. Pathogenic autosomal dominant mutations of this gene significantly increase lifetime cancer risk, particularly breast and pancreatic cancers. We present a case of a 71-year-old African American woman without a known family history of malignancy found to have a heterozygous PALB2 mutation following the diagnoses of metachronous colorectal adenocarcinomas and multiple gynecologic cancers. After the discovery of the mutation, the patient underwent resection of a pancreatic head adenocarcinoma. Moreover, following an incidental discovery of evolving right-breast microcalcifications on a routine mammogram, the patient is pending a biopsy procedure for further investigation. Her positive mutation results prompted genetic testing in her family, leading to the detection of the mutation in both her daughter and granddaughter. This case highlights the importance of hereditary cancer evaluation and multigene testing in patients with multiple primary malignancies. While pancreatic cancer is an established PALB2-associated malignancy, the colorectal, uterine, and vulvar cancers observed in this patient should be interpreted cautiously, as their association with PALB2 remains unestablished. Identification of a pathogenic variant can guide risk-appropriate surveillance and cascade testing.

Indexed as

cascade testingcase reportcolorectal cancergenetic testinggermline mutationhereditary cancerhereditary cancer syndromemetachronous malignanciespalb2pancreatic adenocarcinoma

Identifiers

PMID42689189
PMCPMC13537084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.